Papers 4785
1 page of 479 pages (4,785 results)
#2James Robert Brašić (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 32
#1Shen Lin (Fujian Medical University)H-Index: 3
#2Shaohong Luo (Fujian Medical University)H-Index: 2
Last. Xiuhua Weng (UCSF: University of California, San Francisco)H-Index: 1
view all 9 authors...
Background null The latest published CASPIAN trial demonstrated that adding durvalumab to etoposide and platinum (EP) improved survival dramatically for patients with extensive-stage small cell lung cancer (ES-SCLC). Considering the high cost of durvalumab, this study evaluated the cost-effectiveness of durvalumab plus EP (DEP) in the first-line setting for treatment-naive ES-SCLC patients from the US payer perspective. null Methods null We developed a three-state Markov model to simulate the di...
#1Joerg Trojan (Goethe University Frankfurt)H-Index: 25
#2Sebastian Stintzing (Charité)H-Index: 36
Last. Ivan Jelas (Charité)H-Index: 3
view all 7 authors...
BACKGROUND Patients with colorectal carcinoma and high-grade microsatellite instability (MSI-H) or deficiency in mismatch repair (dMMR) exceptionally respond to immune checkpoint inhibitors (ICIs). ICIs are more active in treatment-naive than in refractory MSI-H/dMMR mCRC patients and even more active in locally advanced tumors. MATERIAL AND METHODS A 33-year old male patient with Lynch syndrome was diagnosed with a locally advanced rectal cancer and refused standard neoadjuvant chemoradiation b...
#1Jianqing Lin (GW: George Washington University)H-Index: 4
#2Jacob M. Elkon (GW: George Washington University)H-Index: 1
Last. Alejandro Villagra (GW: George Washington University)H-Index: 29
view all 10 authors...
LESSONS LEARNED Entinostat at the selected dose levels in combination with a standard dose of enzalutamide showed a promising safety profile in this small phase I study BACKGROUND: Entinostat inhibits prostate cancer (PCa) growth and suppresses Treg cell function in vitro and in vivo. METHODS This was a phase I study to explore the safety and preliminary efficacy of entinostat (3 and 5 mg orally per week) in combination with enzalutamide in castration-resistant PCa (CRPC). The study was carried ...
#1Ran Chu (SDU: Shandong University)H-Index: 1
#2Yue Zhang (SDU: Shandong University)H-Index: 1
Last. Aijun Yin (SDU: Shandong University)H-Index: 3
view all 16 authors...
Background null Adjuvant therapy for cervical cancer (CC) patients with intermediate-risk factors remains controversial. The objectives of the present study are to assess the prognoses of early-stage CC patients with pathological intermediate-risk factors and to provide a reference for adjuvant therapy choice. null Materials and methods null This retrospective study included 481 patients with stage IB-IIA CC. Cox proportional hazards regression analysis, machine learning (ML) algorithms, Kaplan-...
#1Martina Lorenzi (UNIPD: University of Padua)H-Index: 2
#2Alessandra Ferro (UNIPD: University of Padua)H-Index: 5
Last. Rita ChiariH-Index: 29
view all 22 authors...
LESSONS LEARNED Osimertinib has confirmed effectiveness in this real-world population of patients with EGFR-mutant advanced non-small cell lung cancer population. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain metastases, and symptoms at diagnosis seem to have a worse prognosis. BACKGROUND Osimertinib became the standard treatment for patients with un...
#1Nicole Yun (Rush University Medical Center)
#2Jessica Slostad (Rush University Medical Center)
Last. Lydia Usha (Rush University Medical Center)H-Index: 8
view all 7 authors...
BACKGROUND Next-generation sequencing (NGS) technologies have become increasingly used for managing breast cancer. In addition to the conventional use of NGS for predicting recurrence risk and identifying potential actionable mutations, NGS can also serve as a powerful tool to understand clonal origin and evolution of tumor pairs and play a unique role in clarifying complex clinical presentations. PATIENT STORY We report an unusual case of early-stage breast cancer in which the primary tumor and...
#1Natalie Reizine (U of C: University of Chicago)H-Index: 6
#2Keith Danahey (U of C: University of Chicago)H-Index: 10
Last. Monica Malec (U of C: University of Chicago)H-Index: 3
view all 12 authors...
Background null Several opioids have pharmacogenomic associations impacting analgesic efficacy. However, germline pharmacogenomic testing is not routinely incorporated into supportive oncology. We hypothesized that CYP2D6 profiling would correlate with opioid prescribing and hospitalizations. null Patients and methods null We analyzed 61,572 adult oncology patients from 2012-2018 for opioid exposures. CYP2D6 metabolizer phenotype (ultra-rapid [UM], normal metabolizer [NM], intermediate [IM], or ...
#1Benjamin L. Maughan (HCI: Huntsman Cancer Institute)H-Index: 17
#2Adam Kessel (HCI: Huntsman Cancer Institute)H-Index: 2
Last. Manish Kohli (HCI: Huntsman Cancer Institute)H-Index: 34
view all 14 authors...
LESSONS LEARNED Long-term safety of radium-223 with enzalutamide was confirmed in this clinical trial. PSA-PFS2 was prolonged with the combination compared with enzalutamide alone. BACKGROUND Previously, we showed the combination of radium-223 and enzalutamide to be safe and associated with improved efficacy based on a concomitant decline in serum bone metabolism markers compared with enzalutamide alone in a phase II trial of men with metastatic castration resistant prostate cancer (mCRPC) [1]. ...
#1Miao XiangH-Index: 3
#2Xiyue YangH-Index: 2
Last. Yu ZhangH-Index: 2
view all 12 authors...
Lessons learned null The combination of anlotinib and S-1 exhibited good anti-tumor activity in third- or later-line treatment for stage IV non-small cell lung cancer (NSCLC). Combination therapy of anlotinib with S-1 has manageable toxicities in patients with NSCLC. null Abstract null BACKGROUND: This study aimed to evaluate the efficacy and safety of anlotinib combined with S-1 as a third- or later-line treatment for patients with stage IV non-small cell lung cancer (NSCLC). Anlotinib was appr...
Top fields of study
Breast cancer